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Tuberculous meningitis (TBM) is often diagnostically challenging. Only limited data 
exist on the performance of interferon-gamma release assays (IGRA) and molecular 




Multicenter, retrospective study involving 27 healthcare institutions providing care 
for children with tuberculosis (TB) in nine European countries. 
 
Results 
Of 118 children included, 54 (45.8%) had definite, 38 (32.2%) probable and 26 
(22.0%) possible TBM; 39 (33.1%) had TBM grade 1, 68 (57.6%) grade 2 and 11 
(9.3%) grade 3. Of 108 patients who underwent cranial imaging 90 (83.3%) had ≥1 
abnormal finding consistent with TBM. At the 5mm cut-off the tuberculin skin test 
had a sensitivity of 61.9% (95%CI: 51.2-71.6%); at the 10mm cut-off 50.0% (95%CI: 
40.0-60.0%). The test sensitivities of QuantiFERON-TB and T-SPOT.TB assays were 
71.7% (95%CI: 58.4-82.1%) and 82.5% (95%CI: 58.2-94.6%), respectively (p=0.53). 
Indeterminate results were common, occurring in 17.0% of QuantiFERON-TB assays 
performed. Cerebrospinal fluid (CSF) cultures were positive in 50.0% (95%CI: 40.1-
59.9%), and CSF polymerase-chain-reaction (PCR) in 34.8% (95%CI: 22.9-43.7%). 
In the subgroup of children who had TST, IGRA, CSF culture and CSF PCR 




Existing immunological and microbiological TB tests have suboptimal sensitivity in 
children with TBM, with each test producing false-negative results in a substantial 
proportion of patients. Combining immune-based tests with CSF culture and CSF 
PCR results in considerably higher positive diagnostic yields, and should therefore be 
standard clinical practice in high-resource settings. 
 




Globally an estimated one million children and adolescents develop active 
tuberculosis (TB) annually, with the majority of the disease burden occurring in low-
resource countries [1]. In most European countries the incidence of TB disease has 
been declining steadily over the last decades, but drug-resistant Mycobacterium 
tuberculosis, particularly in Eastern Europe, has brought new challenges [2]. 
 
TB meningitis (TBM) is an uncommon manifestation of TB disease, but associated 
with significant morbidity and mortality, even in high-resource settings [3]. Children 
with TBM frequently present with non-specific symptoms and without a history of 
TB contact, and diagnosing TBM is therefore often challenging [4-6]. Importantly, 
previous data suggest that delays in diagnosis are linked to poor outcomes [7]. 
 
TB diagnostics used in routine clinical practice have evolved significantly over the 
last two decades, with the introduction of interferon-gamma release assays (IGRAs) 
and a variety of commercial molecular assays [8]. Recent data show that both IGRAs 
and molecular TB assays are widely available across Europe, and are used extensively 
by paediatric TB specialists [9, 10]. 
 
Immune-based TB tests, comprising tuberculin skin tests (TSTs) and IGRAs, are 
commonly used as adjunctive diagnostic tools in children with suspected TB disease 
[8], but the existing data on the performance of IGRAs specifically in children with 
TBM remain very limited [11, 12]. Also, although a small number of studies have 
investigated the use of molecular TB assays in children with suspected TBM, most of 
these were small, limited to a single study site, or from low-resource settings where 
late presentations are likely more common than in Europe [4, 13, 14]. Furthermore, 
most studies were conducted under protocolised study conditions, and therefore prone 
to overestimating test sensitivity compared to performance in a routine clinical 
setting.  
 
This study aimed to determine the sensitivity of immunological, conventional 
microbiological and molecular TB tests in children with TBM in the context of 
routine clinical care in Europe. Secondary aims were to describe clinical features and 
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radiological findings at presentation, and to evaluate the Uniform TBM Research 






European-countries [9, 10, 15, 16], were-invited-to-retrospectively-report-children-







Classification of cases 
Cases were categorised as definite TB, probable TBM or possible TBM, according to 
consensus definitions based on the Uniform TBM Research Case Definition 
(UTRCD) score (Supplementary Table 1) [3], with minor modifications: a) the item 
‘history of close contact with an individual with pulmonary TB or a positive TST or 
IGRA’, which scores 2 points in the original criteria, was split into two separate items 
i) history of close contact with an individual with pulmonary TB and ii) a positive 
TST ( 10 mm) and/or IGRA, each scoring one point if present. Furthermore, 
‘choroidal tubercles’ was added to the category ‘evidence of tuberculosis elsewhere’, 
scoring one point if present; the maximum category score of 4 was retained. If no data 
was available for one particular item, the respective item was scored as 0. Briefly, 
definite TBM was defined as a patient with clinical entry criteria (headache, 
irritability, vomiting, fever, neck stiffness, convulsions, focal neurological deficits, 
altered consciousness, or lethargy) plus one or more of the following: acid-fast bacilli 
detected in cerebrospinal fluid (CSF), M. tuberculosis cultured from CSF or 
M. tuberculosis detected by polymerase chain reaction (PCR) in CSF. Probable TBM 
was defined as presence of clinical entry criteria plus a total diagnostic score of 12 or 
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more, and possible TBM as presence of clinical entry criteria plus a total diagnostic 




Council-(BMRC)-criteria [17, 18]. In-brief, grade-1-corresponds-to-a-Glasgow-coma-
score-of-15-with-no-neurologic-signs, grade-2-a-score-of 11–14 or-a-score-of-15-






available-(i.e. induration-in-mm), but-the-test-was-reported-to-be-negative, it-was-
classified-as-missing-data-at-the-5-mm-threshold-and-negative-at-the-10-mm-




variables-of-age, sex, BCG-vaccination-status, TBM-staging, and-definite-TBM-
diagnosis. Models-were-evaluated-with-the-Hosmer-Lemeshow-goodness-of-fit-test-
and-Receiver-Operating-Characteristic-curves-showed-an-Area-Under-the-Curve 
0.7. The-primary-outcome-measures-were-odds-ratios (ORs). The-95%CI-was-
calculated-for-each-odds-ratio, and-p-values <0.05 were-considered-significant. 
Analyses-were-done-with-Prism (V8.0; GraphPad, La-Jolla, U.S.) and-Stata (v12.1; 











Twenty-seven healthcare institutions, situated in Bulgaria (n=1), Italy (n=3), Finland 
(n=1), Germany (n=3), Greece (n=1), Slovenia (n=1), Spain (n=12), Sweden (n=2) 
and the United Kingdom (n=3), contributed cases to the study. 
 
A total of 118 children were included in the final analysis, comprising 54 (45.8%) 
definite, 38 (32.2%) probable and 26 (22.0%) possible TBM cases. With regards to 
disease severity, 39 (33.1%) were BMRC TBM grade 1, 68 (57.6%) grade 2 and 11 
(9.3%) grade 3.  
 
The demographic details are shown in Table 1. The median age was 2.7 (IQR:1.1-
6.4) years. Although the majority (89.8%) of children had been born in Europe, 
almost half of these (48.3%) were from families with one or both parent(s) originating 
from a high TB prevalence country. Almost half (41.5%) had a history of TB contact. 
A test for human immunodeficiency virus was performed in 73 (61.9%) children; only 
two (2.7%) were positive.  
 
The commonest constitutional symptom at presentation was fever. The most common 
neurological symptoms at presentation comprised vomiting, headache and altered 
level of consciousness (Table 1). 
 
Distribution of the UTRCD score among subgroups 
In the group of patients with definite TBM mean score was 12.8 (standard deviation 
(SD):3.1;range:4-19). In the patients with probable or possible TBM combined, the 
mean score was 12.1 (SD:2.8;range:6-18). Of the children with definite TBM, almost 
one third (n=17;31.5%) had scores <12 (Figure 1).  
 
Radiological investigations 
Of 112 patients who underwent chest x-rays, 81 (72.3%) had changes suggestive of 
intrathoracic TB disease, including hilar lymphadenopathy, pulmonary infiltrates, 




Sixty-five patients had an abdominal ultrasound scan. In the majority (64.6%) no 
abnormalities were detected. The most common abnormal findings were 
hepatomegaly, splenomegaly and intrabdominal granulomas (Table 2). 
 
In 108 patients cranial imaging with computed tomography and/or magnetic 
resonance imaging was performed. Of those, 90 (83.3%) had one or more abnormal 
findings consistent with TBM. The most common finding was hydrocephalus, 
followed by basal meningeal enhancement and intracranial tuberculomas (Table 2). In 
the remaining 18 (16.7%) patients no significant abnormalities were identified, which 
included six children with definite TBM. 
 
Performance of immunological TB tests 
TST, QuantiFERON Gold assay and T-SPOT.TB assay (both performed on blood 
samples) results were available in 92, 53 and 17 patients, respectively. In 10 patients 
neither TST nor IGRA results were available. 
 
Table 3 summarises the results of 108 patients in whom TST and/or IGRA results 
were available. Of the 54 children in whom both TST and IGRA results were 
available only six (11.1%) had concordantly negative TST (at the 10 mm threshold) 
and IGRA results; five (9.3%) had negative TST and indeterminate QFT results; in 
the remaining 43 (79.6%) at least one immunological test result was positive. 
 
At the 5 mm cut-off the TST had a sensitivity of 61.9% (95%CI:51.2-71.6%), and at 
the 10 mm cut-off 50.0% (95%CI:40.0-60.0%). The sensitivities of the QFT and the 
T-SPOT.TB assay were 71.7% (95%CI:58.4-82.1%) and 82.5% (95%CI:58.2-94.6%), 
respectively. Statistically, there was no significant difference between the sensitivity 
of the TST at the 5 mm cut-off and the QFT assay (0.27); however, there was a 
significant difference at the 10 mm cut-off (p=0.0143). Similarly, no significant 
difference was detected between the TST at 5 mm and the T-SPOT.TB assay 
(p=0.16), but there was a significant difference at the 10 mm cut-off (p=0.0167). 
There was no statistically significant difference between the sensitivity of both IGRA 
assays (p=0.53). The proportion of positive TST results (at the 10 mm cut-off) did not 
differ significantly between BCG-vaccinated and BCG non-vaccinated children 
(47.1% vs. 52.5%; p=0.78); also, there was no significant difference between those 
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two subgroups with regards to TST induration size (median 8 mm vs. 10 mm, 
respectively; p=0.81). 
 
Of the 53 patients with QFT results, 9 (17.0%) had an indeterminate test result (95% 
CI:9.0-29.5%). In the 17 patients with T-SPOT.TB results, there were no 
indeterminate results. There was no statistical difference between both IGRAs with 
regards to the proportion of indeterminate versus determinate (i.e. positive or 
negative) results (p=0.10). On average children with indeterminate test results were 
younger (median age:2.0 years;IQR:1.4-3.0 years) than children with determinate 
results (median:2.7 years;IQR:1.0-6.5 years), although this did not reach statistical 
significance (p=0.22) (Supplementary Table 2).  
 
Cerebrospinal fluid results 
The cerebrospinal fluid results at initial presentation in the 106 patients in whom these 
data were available are summarised in Figure 2 and Supplementary Table 3. Only 
10 (9.4%) patients had CSF protein concentrations within the normal range (0-0.4 
g/L); in 57 (53.8%) the CSF protein concentration was ≥1.0 g/L.   
 
Performance of microbiological tests with cerebrospinal fluid 
Results of acid-fast stains, mycobacterial culture and MTB PCR testing on CSF were 
available in 75, 94 and 69 patients, respectively. Only three (4.0%) cases were 
positive for acid-fast bacilli (95%CI of sensitivity:0.9-11.6). A total of 47 (50.0%) 
had positive mycobacterial culture results (95%CI:40.1-59.9%), while only 24 
(34.8%) cases were positive on PCR testing (95%CI:22.9-43.7%), although this did 
not reach statistical significance (p=0.06). Of the 62 cases in whom both 
mycobacterial culture and PCR had been performed on CSF, 17 were positive in both 
tests, 15 were positive only in culture, and 4 positive only in PCR. In this subgroup 
performing both tests in parallel achieved greater sensitivity (36/62;58.1%; 
95%CI:45.7-69.5%) than performing either culture (32/62;51.6%; 95%CI:39.5-
63.6%) or PCR alone (21/62;33.9%; 95%CI:23.3-46.3%), but only the comparison 





Combining immunological and microbiological tests 
Figure 3 summarizes the results of the subgroup of patients in whom both 
immunological and both mycobacterial culture and PCR on CSF had been performed 
(n=32), showing that TST+/IGRA+/CSF culture+ and IGRA+ only were the most 
common result constellations, but also that result constellations were very 
heterogeneous. Only 5 (15.6%) cases had negative results in all four tests; therefore, 
the overall sensitivity of all four tests combined was 84.4% (95%CI:67.8%-93.6%). 
Only one of those 5 cases had sampling performed at another site, a lymph node 
biopsy that was culture- and PCR-positive for MTB. 
 
Multivariate logistic regression analyses 
The results of the multivariate regression analyses for having a positive 
immunological test result are summarised in Table 4. Children with TBM grade 3 
were significantly less likely to have a positive TST (at both the 5 mm [OR 
0.08;p=0.019] and the 10 mm cut-off [OR 0.06;p=0.023]) than those with TBM 
grade 1. This was however not a statistically significant predictor of a positive IGRA 
result (OR 0.13;p=0.13). Younger children were more likely to have a positive IGRA 
result (OR 0.7 per year increasing age;p=0.042). There were no statistically 
significant predictor variables of an indeterminate IGRA result in multivariate 
analysis (Supplementary Table 2).  
 
Detection of Mycobacterium tuberculosis at other sites 
In 56 (47.5%) patients MTB was detected in at least one clinical sample other than 
CSF (Table 5). Of those 49 (87.5%) were culture-positive and 27 (48.2%) were PCR-
positive; 20 (35.7%) were positive in both culture and PCR. Among the 64 cases with 
possible and probable TBM (i.e. in whom M. tuberculosis was not identified in the 
CSF), M. tuberculosis was identified by culture and/or PCR at another site in 30 





To our knowledge this study is the largest multi-center study on TBM in children 
from a low TB incidence setting to date, facilitated by inclusion of a large number of 
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participating centers across Europe via a well-established collaborative paediatric TB 
research network.  
 
That this study was conducted in a low TB incidence setting is relevant for the 
interpretation of its findings. Almost a third (33.1%) of the cases had BMRC TBM 
grade 1 disease, while only 9.3% had grade 3 disease, contrasting with reports from 
high TB incidence countries, where the vast majority of patients have grade 2 or grade 
3 disease at presentation [13]. This indicates that in the European setting there is a 
tendency for patients with TBM to present earlier and with less severe disease. 
 
In addition, our cohort differs from most cohorts of children with TBM reported from 
high TB prevalence countries with regards to the proportion of cases that are 
microbiologically-confirmed. Almost half (45.8%) of the cases in our cohort were 
confirmed, contrasting with studies from high prevalence settings in which fewer than 
a quarter are confirmed cases [14, 19, 20]. This may be the result of recall bias and 
preferential reporting of confirmed cases in our study, or alternatively reflect the 
greater availability of diagnostic tests at the centres that participated in this study 
compared to lower resource settings. The latter hypothesis is supported by the fact 
that paediatric studies in high TB prevalence settings with access to molecular 
diagnostics have reported similar proportions of microbiologically-confirmed cases 
[4, 21].  
 
The performance of the UTRCD scoring system, which is based on expert consensus 
[3], was suboptimal in our cohort. Almost one third (31.5%) of cases with 
microbiologically-confirmed TBM had scores below 12, which in the absence of a 
positive microbiological result would categorise those patients as ‘possible TBM’. It 
is possible that the comparatively poor performance relates to the tendency for 
European patients to present earlier - and therefore with fewer features and 
consequently lower scores - than patients in high TB prevalence settings. However, in 
some patients certain data required for scoring (e.g. symptom duration) were not 
recorded, potentially resulting in the UTRCD scores of those patients being skewed 
towards lower values. However, importantly, this scoring system was developed for 
research purposes, and not for clinical decision-making.   
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Radiological changes suggestive of intrathoracic TB disease were present in almost 
three quarters (72.3%) of the cases. This highlights that patients with suspected TBM 
should routinely undergo chest imaging as this is likely to provide useful information 
aiding diagnosis. However, our data contrasts with data from other studies that 
reported chest x-ray changes in considerably lower proportions of children with TBM, 
typically 40-60% [19, 22, 23]. The observation that a high proportion (83.3%) of 
children in our cohort had abnormal findings on cranial imaging, including 
hydrocephalus, basal meningeal enhancement and intracranial tuberculomas, is 
consistent with previous reports [19, 20, 22]. 
 
Our data highlight that all existing immunological and microbiological TB tests have 
suboptimal sensitivity in children with TBM. TST, QFT assays and T-SPOT.TB 
assays had sensitivities around 80% or below, indicating that approximately 1 in five 
children with TBM have a false-negative result when a single immunological test is 
performed, irrespective of which test is used. Several recent studies, including in 
patients with TBM, have investigated novel immune-based TB biomarkers in blood 
that have the potential to improve the diagnosis of TB in children, but additional 
studies will be required to confirm their findings [24-26]. Interestingly, our 
multivariate logistic regression analyses indicate that false-negative TST results were 
more common in children with more severe TBM. Furthermore, we found that a large 
proportion of patients had discordant TST and IGRA results, in accordance with 
observations reported by studies in children with pulmonary TB [24, 27, 28].  
 
It was striking that a substantial proportion of children had indeterminate IGRA test 
results. Among children who had undergone testing with QFT assays 17.0% had an 
indeterminate result, which is considerably higher than in most studies that 
investigated the performance of QFT assays in children with pulmonary TB [24, 27, 
29, 30]. Interestingly, the association between tuberculous CNS disease and 
indeterminate IGRA results was also observed in Californian study, although it only 
included 17 confirmed cases with CNS disease [11]. Although the basis for these 
observations remains uncertain, it is tempting to hypothesise that age is a contributing 
factor, considering that the median age of our cohort was 2.6 years, but we did not 
detect an association between age and indeterminate test results in multivariate 
logistic regression analyses. Nevertheless, several published studies, including our 
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own, have shown that young age is associated with indeterminate IGRA results [31-
33]. Alternatively, there may be immunological differences between children with 
TBM and those with pulmonary TB resulting in impaired IGRA performance in the 
former.  
 
In accordance with published data our results show that AFB stain microscopy has 
very poor sensitivity in children with TBM [7, 14, 22]. Mycobacterial culture 
performed on CSF was the microbiological test with the highest sensitivity, but still 
only positive in half of the cases. PCR for MTB performed on CSF had even lower 
sensitivity, producing a positive result in only about one in three cases. However, the 
fact that a variety of in-house and commercial PCR assays were used at different 
healthcare institutions limit the interpretation of this finding. A recent study that 
included 23 HIV-infected adults with TBM found that the recently released Xpert 
MTB/RIF Ultra assay had higher sensitivity than both the previous generation Xpert 
MTB/RIF assay and culture (sensitivity 70% vs. 43% and 43%, respectively) [34], 
suggesting that some commercial PCR-based assays may perform as well as culture 
or potentially even have superior sensitivity in TBM. However, larger prospective 
studies are needed to confirm those findings. Our data show that performing both 
culture and PCR on CSF in parallel increases the diagnostic yield, in concordance 
with observations in a paediatric study from South-Africa [21]. A recent publication 
raises hopes that metagenomic next generation-sequencing of CSF could potentially 
improve the diagnosis of CNS infections with organisms that are difficult to detect 
with existing microbiological methods [35].   
 
In addition, our data show that in the large majority of children with TBM at least one 
test produces a positive result if TST, IGRA, CSF culture and CSF PCR are 
performed in parallel, as only 15.6% of the cases showed false-negative results in all 
four tests. In the paediatric setting immunological tests are often used as adjunctive 
tests in suspected TB disease [8], a practice that is supported by our findings. 
Although positive immunological tests do not confirm TB disease, in a child with 
compatible clinical and radiological findings they lend substantial support to a 
putative diagnosis of TBM.  
 
 15 
In a substantial number of children in this cohort MTB was detected in samples other 
than CSF, helping to secure a microbiological diagnosis. Sputum, gastric aspirates 
and BAL fluid samples all had high yields, universally with a positive detection rate 
of 75% or greater. However, considering that decisions to obtain those samples were 
made by clinicians managing the patients, rather than according to a standardised 
study protocol, it is probable that these samples were preferentially obtained in a 
selected group of patients who had chest x-ray changes or respiratory symptoms. 
Nevertheless, our data highlight that testing respiratory/gastric samples should be 
done routinely in children with suspected TBM, as M. tuberculosis can often not be 
detected in CSF, precluding microbiological confirmation and susceptibility testing. 
 
As with all retrospective studies, a key limitation of this study was that some data 
were missing due to incomplete documentation. A larger number of patients had TSTs 
performed, but only categorical rather than quantitative data were documented, 
resulting in those patients having to be excluded from some of the analyses. Also, 
only a small number of participating centres were using T-SPOT.TB assays; 
consequently, the data on the performance of this test were limited. None of the 
patients had an IGRA performed on CSF; however, a recent meta-analysis has shown 
that performing IGRAs on CSF rather than blood does not result in a higher 
diagnostic yield [12].  Finally, in common with all retrospective studies there is a risk 
of recall bias and preferential reporting.  
 
In conclusion, our data show that in the European setting children with TBM tend to 
present earlier and with less severe disease than in high TB incidence settings. A large 
proportion of children with TBM have co-existing intrathoracic TB disease, and 
consequently chest imaging and collection of respiratory or gastric samples should be 
considered in all patients with suspected TBM. Both immunological (TST and 
IGRAs) and microbiological TB tests have suboptimal sensitivity in children with 
TBM. Performing both TST and IGRA in parallel with microbiological testing of CSF 
by culture and PCR results in a substantial increase in the proportion of children who 
have evidence of TB infection, which should therefore be the standard approach in 
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Median age (IQR) 2.7 years  
(1.1 - 6.4) 
Male : female ratio 1.1 : 1.0 
Born in Europe 106 (89.8%) 
Born in Europe with one or both parent(s) originating from a high 
TB incidence country 
57 (48.3%) 
Born outside Europe 
     Africa  
     Asia  





Prior BCG vaccination 
     Yes 
     No 





Known TB contact 
     Yes 
     No 





Constitutional symptoms at presentation 
     Fever 
     Weight loss 





Neurological symptoms at presentation 
     Vomiting 
     Altered consciousness  
     Headache  
     Lethargy  
     Cranial nerve palsy  
     Seizures  
     Ataxia 










*unless specified otherwise 















Table 2. Radiological findings on chest x-ray, abdominal ultrasound scan and cranial 
imaging with computed tomography or magnetic resonance imaging 
 
 No. (percentage) 
Chest x-ray (n=112) 
   Changes suggestive of active TB * 
   Changes suggestive of previous pulmonary TB ** 





Abdominal ultrasound scan (n=65) 
   Hepatomegaly 
   Splenomegaly 
   Intraabdominal granulomas 
   Miliary lesions 
   Enlarged lymph nodes 








Cranial CT / MRI (n=108) 
   Hydrocephalus 
   Basal meningeal enhancement 
   Intracranial tuberculomas 
   Cerebral infarcts 








* hilar adenopathy, pulmonary infiltrates, consolidation or cavitation 
** fibrotic scars or calcification 









Table 3. Summary of tuberculin skin test and interferon-gamma release assay 












































































* IGRA not performed or result not available 
** Excludes 8 patients who were negative at the 10 mm cut-off, but had no quantitative result recorded  
*** TST not performed or result not available 
Abbreviations: IGRA: interferon-gamma release assay, indet.: indeterminate, neg.:negative, 








Table 4. Multivariate logistic regression analysis for association between positive 
tuberculin skin test at the 5 mm and the 10 mm threshold, and positive interferon-
gamma release assay result (IGRA+) as outcome variable, and predictor variables of 
age, sex, BCG vaccination status, TB meningitis staging, definite TB meningitis 
diagnosis and IGRA type (for IGRA result only). Indeterminate IGRA results were 








Odds Ratio  
(95% CI) 
P value 
Age (years) Continuous 
TST 5 mm 
0.89  
(0.78, 1.02) 0.100 
TST 10 mm 
0.90  
(0.79, 1.02) 0.103 
IGRA+ 
0.70  
(0.50, 0.99) 0.042 
Male Binary 
TST 5 mm 
0.43  
(0.14, 1.29) 0.133 
TST 10 mm 
0.61  
(0.22, 1.66) 0.331 
IGRA+ 
0.66  
(0.16, 2.69) 0.560 
BCG status Binary 
TST 5 mm 
1.60  
(0.33, 7.71) 0.560 
TST 10 mm 
1.27  
(0.29, 5.50) 0.751 
IGRA+ 
1.52  





(stage 2 compared 
to  
stage 1) 
TST 5 mm 
0.36  
(0.11, 1.21) 0.100 
TST 10 mm 
0.43  
(0.15, 1.25) 0.121 
IGRA+ 
0.25 
(0.03, 1.85) 0.180 
(stage 3 compared 
to  
stage 1) 
TST 5 mm 
0.08  
(0.01, 0.65) 0.019 
TST 10 mm 
0.06  
(0.00, 0.68) 0.023 
IGRA+ 
0.13  






TST 5 mm 
0.71  
(0.24, 2.10) 0.540 
TST 10 mm 
0.37  
(0.13, 1.03) 0.056 
IGRA+ 
0.82  





compared to QFT 
IGRA+ 
22.15  






Table 5. Summary of microbiological test results of samples other than cerebrospinal 
fluid. 
 
Type of sample Total no. of 
patients with 



















































Supplementary Table 1. Uniform TB Meningitis Research Case Definition scoring 
system (adapted from Marais et al. (3)) 
 





Symptom duration of more than 5 days 4 
Systemic symptoms suggestive of TB (one or more of the following): weight loss (or poor 
weight gain in children), night sweats, or persistent cough for more than 2 weeks 
2 
History of recent (within past year) close contact with an individual with pulmonary TB or a 
positive TST or IGRA (only in children <10 years of age) 
2 
Focal neurological deficit (excluding cranial nerve palsies) 1 
Cranial nerve palsy 1 





Clear appearance 1 
Cells: 10–500 per μl 1 
Lymphocytic predominance (>50%) 1 
Protein concentration greater than 1 g/L 1 
CSF to plasma glucose ratio of less than 50% or an absolute CSF glucose concentration 
less than 2.2mmol/L 
1 
 




Basal meningeal enhancement 2 
Tuberculoma 2 
Infarct 1 
Pre-contrast basal hyperdensity 2 
 
Evidence of TB elsewhere 
(Maximum category 
score=4) 
Chest radiograph suggestive of active TB: signs of TB=2; miliary TB=4 2/4 
   CT / MRI / ultrasound evidence for TB outside the CNS 2 
AFB identified or Mycobacterium tuberculosis cultured from another source—ie, sputum, 
lymph node, gastric washing, urine, blood culture 
4 
Positive commercial Mycobacterium tuberculosis NAAT from extra-neural specimen 4 
 
Exclusion of alternative diagnoses 
 
Abbreviations: AFB = acid-fast bacilli; CNS = central nervous system; CSF = cerebrospinal fluid; CT = computed tomography; 




Supplementary Table 2. Multivariate logistic regression analysis for association 
between indeterminate interferon-gamma release assay result as outcome variable, 
and predictor variables of age, sex, BCG vaccination status, TB meningitis staging 
and classification.  
 
Predictor variable Descriptor  Odds Ratio  
(95% CI) 
P value 















(stage 2 compared 




(stage 3 compared 














compared to QFT 
- - 







Supplementary Table 3. Cerebrospinal fluid laboratory results at initial presentation 
in patients in whom those data were available (n=106). 
 
  Median IQR 
White blood cell count 110 / µL 55 – 296 / µL 
Neutrophil percentage 12% 5 – 30% 
Lymphocyte percentage 82% 64 – 95% 
Protein concentration 1.18 g/L 0.67 – 1.79 g/L 
Glucose concentration 1.50 mmol/L 1.08 – 2.22 mmol/L 





Figure 1. Distribution of modified Uniform Tuberculous Meningitis Research Case 




























Modified Uniform TBM Research Case Definition scores
 29 
Figure 2. Violin plots of cerebrospinal fluid (CSF) white blood cell counts (WBC), 
protein and glucose concentrations at initial presentation. The lines indicate the 






Figure 3. Venn diagram summarising positive tuberculin skin test (TST), interferon-
gamma release assay (IGRA) and cerebrospinal fluid test results (CSF culture and 
PCR) in the subgroup of patients who had all four tests performed (n=32). In five of 







Supplementary Figure 1: Distribution of categorical interferon-gamma release 





































n=21 n=29 n=8 n=11
